A detailed history of Rhumbline Advisers transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,628 shares of PBYI stock, worth $146,411. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,628
Previous 50,270 7.24%
Holding current value
$146,411
Previous $163,000 27.61%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.25 - $4.03 $8,194 - $14,677
-3,642 Reduced 7.24%
46,628 $118,000
Q2 2024

Aug 01, 2024

BUY
$2.92 - $5.83 $140,697 - $280,912
48,184 Added 2309.88%
50,270 $163,000
Q2 2023

Aug 08, 2023

BUY
$2.6 - $3.58 $5,423 - $7,467
2,086 New
2,086 $7,000
Q2 2022

Aug 11, 2022

SELL
$1.64 - $3.3 $63,590 - $127,957
-38,775 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$2.13 - $3.24 $8 - $12
4 Added 0.01%
38,775 $112,000
Q4 2021

Feb 10, 2022

SELL
$2.85 - $6.58 $2,388 - $5,514
-838 Reduced 2.12%
38,771 $118,000
Q3 2021

Nov 12, 2021

BUY
$6.63 - $9.39 $3,765 - $5,333
568 Added 1.45%
39,609 $278,000
Q2 2021

Aug 05, 2021

SELL
$8.98 - $11.6 $21,983 - $28,396
-2,448 Reduced 5.9%
39,041 $358,000
Q1 2021

May 06, 2021

SELL
$9.38 - $13.63 $35,456 - $51,521
-3,780 Reduced 8.35%
41,489 $403,000
Q4 2020

Feb 10, 2021

BUY
$7.78 - $12.13 $25,362 - $39,543
3,260 Added 7.76%
45,269 $464,000
Q3 2020

Nov 12, 2020

SELL
$9.5 - $11.14 $67,089 - $78,670
-7,062 Reduced 14.39%
42,009 $424,000
Q2 2020

Aug 13, 2020

BUY
$7.01 - $13.24 $51,173 - $96,652
7,300 Added 17.48%
49,071 $512,000
Q1 2020

May 06, 2020

BUY
$6.28 - $14.57 $2,191 - $5,084
349 Added 0.84%
41,771 $353,000
Q4 2019

Feb 05, 2020

BUY
$6.5 - $10.73 $5,804 - $9,581
893 Added 2.2%
41,422 $362,000
Q3 2019

Oct 23, 2019

SELL
$8.75 - $12.85 $2,117 - $3,109
-242 Reduced 0.59%
40,529 $436,000
Q2 2019

Aug 14, 2019

BUY
$12.3 - $35.76 $25,411 - $73,880
2,066 Added 5.34%
40,771 $518,000
Q1 2019

May 01, 2019

SELL
$20.77 - $42.37 $4,839 - $9,872
-233 Reduced 0.6%
38,705 $1.5 Million
Q4 2018

Jan 31, 2019

BUY
$20.07 - $46.7 $248,566 - $578,379
12,385 Added 46.64%
38,938 $792,000
Q3 2018

Nov 07, 2018

SELL
$41.2 - $59.85 $71,729 - $104,198
-1,741 Reduced 6.15%
26,553 $1.22 Million
Q2 2018

Aug 06, 2018

BUY
$48.3 - $68.25 $6,423 - $9,077
133 Added 0.47%
28,294 $1.67 Million
Q1 2018

May 02, 2018

SELL
$59.7 - $99.25 $53,371 - $88,729
-894 Reduced 3.08%
28,161 $1.92 Million
Q4 2017

Feb 09, 2018

SELL
$93.85 - $132.45 $538,605 - $760,130
-5,739 Reduced 16.49%
29,055 $2.87 Million
Q3 2017

Nov 06, 2017

BUY
$72.0 - $119.75 $2.51 Million - $4.17 Million
34,794
34,794 $4.17 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $143M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.